SOURCE: Sanguine Corporation

April 29, 2010 06:00 ET

SGN Life Sciences Launches PHER-O2 Sales to Preclinical Market

PASADENA, CA--(Marketwire - April 29, 2010) - Sanguine Corporation (OTCBB: SGUI), a bio-pharmaceutical company focused on the development of oxygen-carrying products for use in biomedical and medical device applications including the intravenous transport of diagnostic and potentially therapeutic imaging compounds used for Metabolic Magnetic Resonance Imaging announces that the Company has recently begun development of a new website geared towards the pre-clinical marketplace in order to begin marketing PHER-O2. The Company's website, www.sanguine-corp.com, is expected to display substantial changes in the near future.

Mr. Frank Marra, a Company spokesperson, stated, "The Company has been working with several groups in the development and deployment of metabolic imaging products using PHER-O2 as its primary carrier. There has been significant interest from these groups, the academic communities, the U.S. Military, international bio-device development groups, and others, to pursue a commercial relationship using PHER-O2. Therefore, management has decided that it's time to accommodate these orders and to capitalize on sales of the product, under material transfer agreements, to other members of this community, which has grown substantially over the past 5 years."

Thomas Dress, PhD, SGN Life Sciences' CEO, added, "During our development of PHER-O2 as a blood alternative, we realized its incredible oxygen carrying capabilities. This led us to determine that PHER-O2 has multiple prospective additional applications including: transfusion recipients, heart attack and stroke victims and other applications, with the intent of seeing that PHER-O2 is in every emergency room (ER) and ambulance across the U.S. The total market potential for PHER-O2 is estimated at more than $7 billion in the U.S. alone. We believe that our product is far superior to any other product currently in the industry."

Marra added, "The aggregate pre-clinical market for all products is estimated to be approximately $300 million, annually. This market, while certainly not being our primary target, cannot be ignored and their appetite for PHER-O2 is significant and hopefully will lead to new opportunities."

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

Contact Information

  • For information related to the Sanguine Corporation, contact:

    Investor Relations:
    Michael Dancy
    801-746-3570
    email: Email Contact